New combo attack shrinks advanced head-and-neck cancer in early trial
NCT ID NCT05524168
First seen Jan 19, 2026 · Last updated May 01, 2026 · Updated 11 times
Summary
This study tests whether combining targeted radiation (SBRT), an immunotherapy drug (PD-1 antibody), and chemotherapy can help control nasopharyngeal cancer that has spread to up to five spots in the body. About 41 adults who have not had prior treatment for their advanced cancer will receive this triple therapy. The main goal is to see how long the cancer stays under control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
Conditions
Explore the condition pages connected to this study.